GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » MedAvail Holdings Inc (OTCPK:MDVLQ) » Definitions » Debt-to-EBITDA

MedAvail Holdings (MedAvail Holdings) Debt-to-EBITDA : -0.12 (As of Jun. 2023)


View and export this data going back to 2020. Start your Free Trial

What is MedAvail Holdings Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

MedAvail Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.21 Mil. MedAvail Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $2.06 Mil. MedAvail Holdings's annualized EBITDA for the quarter that ended in Jun. 2023 was $-19.68 Mil. MedAvail Holdings's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 was -0.12.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for MedAvail Holdings's Debt-to-EBITDA or its related term are showing as below:

MDVLQ' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.71   Med: -0.24   Max: -0.06
Current: -0.06

During the past 4 years, the highest Debt-to-EBITDA Ratio of MedAvail Holdings was -0.06. The lowest was -0.71. And the median was -0.24.

MDVLQ's Debt-to-EBITDA is ranked worse than
100% of 421 companies
in the Healthcare Providers & Services industry
Industry Median: 2.58 vs MDVLQ: -0.06

MedAvail Holdings Debt-to-EBITDA Historical Data

The historical data trend for MedAvail Holdings's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedAvail Holdings Debt-to-EBITDA Chart

MedAvail Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Debt-to-EBITDA
-0.71 -0.15 -0.30 -0.17

MedAvail Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.69 -0.32 -0.19 -0.05 -0.12

Competitive Comparison of MedAvail Holdings's Debt-to-EBITDA

For the Pharmaceutical Retailers subindustry, MedAvail Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MedAvail Holdings's Debt-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, MedAvail Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where MedAvail Holdings's Debt-to-EBITDA falls into.



MedAvail Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

MedAvail Holdings's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.708 + 6.367) / -41.765
=-0.17

MedAvail Holdings's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.208 + 2.056) / -19.676
=-0.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2023) EBITDA data.


MedAvail Holdings  (OTCPK:MDVLQ) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


MedAvail Holdings Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of MedAvail Holdings's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


MedAvail Holdings (MedAvail Holdings) Business Description

Traded in Other Exchanges
N/A
Address
4720 East Cotton Gin Loop, Suite 220, Phoenix, AZ, USA, 85040
MedAvail Holdings Inc is a telehealth-enabled pharmacy technology company. It operates in two segments: Retail Pharmacy Services and Pharmacy Technology. It generates the majority of revenue from the Retail Pharmacy Services segment, which is into operating SpotRx, a full-service retail pharmacy utilizing MedAvail's automated pharmacy technology, primarily servicing Medicare patients in the United States. The Pharmacy Technology segment develops and commercializes the MedCenter for direct sale or lease to third-party customers.
Executives
Ramona Seabaugh officer: Chief Financial Officer C/O MEDAVAIL TECHNOLOGIES INC., 6665 MILLCREEK DR, UNIT 1, MISSISSAUGA A6 L5N 5M4
Michael R Kramer director 3910 BRICKWAY BLVD, SANTA ROSA CA 95403
Paul D Johnson director 440 N BARRANCA AVE #3550, COVINA CA 91723
Glen D. Stettin director C/O EXPRESS SCRIPTS HOLDING COMPANY, ONE EXPRESS WAY, ST. LOUIS MO 63121
Mark Edward Doerr director, officer: Chief Executive Officer C/O MEDAVAIL TECHNOLOGIES INC., 6665 MILLCREEK DR, UNIT 1, MISSISSAUGA A6 L5N 5M4
Abg Wtt-medavail Ltd 10 percent owner 15 QUEENS ROAD CENTRAL, UNIT 3002-3004, 30TH FLOOR, GLOUCESTER TWR, THE LANDMARK, HONG KONG F4 0000000000
Redco Ii Master Fund, L.p. director, 10 percent owner ONE LETTERMAN DRIVE, BLDG D, STE D3-300, SAN FRANCISCO CA 94129
Alyeska Fund Gp, Llc 10 percent owner 77 WEST WACKER DRIVE, 7TH FLOOR, CHICAGO IL 60601
Alyeska Investment Group, Llc 10 percent owner 77 WEST WACKER DRIVE, 7TH FLOOR, CHICAGO IL 60601
Alyeska Investments, Llc 10 percent owner 77 WEST WACKER DRIVE, 7TH FLOOR, CHICAGO IL 60601
Anand Parekh 10 percent owner 77 WEST WACKER DRIVE, 7TH FLOOR, CHICAGO IL 60601
Alyeska Master Fund, L.p. 10 percent owner 77 WEST WACKER DRIVE, 7TH FLOOR, CHICAGO IL 60601
Alyeska Investment Group, L.p. 10 percent owner 77 WEST WACKER DRIVE, 7TH FLOOR, CHICAGO IL 60601
Steven Hess officer: Executive Vice President C/O MEDAVAIL TECHNOLOGIES INC., 6665 MILLCREEK DR, UNIT 1, MISSISSAUGA A6 L5N 5M4
Edwin Kilroy director, officer: Chief Executive Officer C/O MEDAVAIL TECHNOLOGIES INC., 6665 MILLCREEK DR, UNIT 1, MISSISSAUGA A6 L5N 5M4

MedAvail Holdings (MedAvail Holdings) Headlines